.
How did Gritstone Bio, a small rock stock focused on cancer vaccines, move on Tuesday?
On Tuesday, Gritstone Bio Inc (NASDAQ Resonance: GRTS) released preliminary data from the Phase 2 portion of the ongoing Phase 2/3 signal-seeking study evaluating the therapeutic efficacy of the personalized neoantigen cancer vaccine, GRANITE, in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC). The study was designed to quantify the clinical benefit of GRANITE (GRT-C901/GRT-R902) combined with immune checkpoint blockade therapy and fluoropyrimidine/bevacizumab maintenance therapy versus fluoropyrimidine/bevacizumab maintenance therapy.
English 
Chinese